Kringle Pharma (TSE:4884) FCF Margin %: 0.00% (As of Mar. 2026)


TSE:4884 Kringle Pharma Inc TSE:4884
40 GF Score
Price 円318.00
GF Value 円497.82
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma FCF Margin %?

Kringle Pharma TSE:4884 +2.91% 40 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates TSE:4884 with a GF Score™ of 40/100 and a GF Value™ of 円497.82 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 959 Biotechnology companies, Kringle Pharma ranks worse than 79.87% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kringle Pharma's Free Cash Flow for the three months ended in Mar. 2026 was 円0.00 Mil. Kringle Pharma's Revenue for the three months ended in Mar. 2026 was 円18.17 Mil. Therefore, Kringle Pharma's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Kringle Pharma's current FCF Yield % is -29.41%.

The historical rank and industry rank for Kringle Pharma's FCF Margin % or its related term are showing as below:

TSE:4884' s FCF Margin % Range Over the Past 10 Years
Min: -1046.57   Med: -509.83   Max: 4.03
Current: -1034.99

During the past 8 years, the highest FCF Margin % of Kringle Pharma was 4.03%. The lowest was -1046.57%. And the median was -509.83%.

TSE:4884's FCF Margin % is ranked worse than
79.87% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs TSE:4884: -1034.99

Kringle Pharma FCF Margin % Related Terms

Kringle Pharma FCF Margin % Historical Data

* Premium members only.

The historical data trend for Kringle Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kringle Pharma FCF Margin % Chart

Kringle Pharma Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
FCF Margin %
Get a 7-Day Free Trial -193.58 4.03 -995.08 -826.07 -1,046.57

Kringle Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSE:4884 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Kringle Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kringle Pharma FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kringle Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Kringle Pharma's FCF Margin % falls into.


TSE:4884
40GF Score
Kringle Pharma Inc TSE:4884
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kringle Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Kringle Pharma's FCF Margin for the fiscal year that ended in Sep. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=-755.782/72.215
=-1,046.57 %

Kringle Pharma's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=0/18.166
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Kringle Pharma (TSE:4884) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kringle Pharma and its competitors. According to the industry distribution chart, Kringle Pharma ranks #766 out of 959 companies in the Biotechnology industry, placing it in the top 79.9%.
Is Kringle Pharma's FCF Margin % too high?
Kringle Pharma's current FCF Margin % is 0.00%. Based on the distribution chart, Kringle Pharma ranks #766 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kringle Pharma has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kringle Pharma ranks #766 out of 959 companies for FCF Margin %. This places Kringle Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円497.82, compared to a current price of 円318.00 — trading 36.1% below its estimated fair value. The current FCF Margin % is 0.00%. Kringle Pharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円318.00 is trading 36.1% below its estimated GF Value™ of 円497.82. GuruFocus considers Kringle Pharma to be Possible Value Trap.

Key valuation signals for TSE:4884:

  • FCF Margin %: 0.00%
  • GF Value™: 円497.82 vs. price of 円318.00 (36.1% below fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
40GF Score

Get the complete analysis for TSE:4884

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円318.00
Price
円497.82
GF Value